1 Humoral immune response and prolonged PCR positivity in a cohort of 1343

2 SARS-CoV 2 patients in the New York City region

Authors: Ania Wajnberg MD, Mayce Mansour, MD, Emily Leven, MD, Nicole M. Bouvier,
MD, Gopi Patel, MD, Adolfo Firpo, MD, Rao Mendu, PhD, Jeffrey Jhang, MD, Suzanne
Arinsburg, DO, Melissa Gitman, MD MPH, Jane Houldsworth, PhD, Ian Baine, MD PhD,
Viviana Simon, MD PhD, Judith Aberg, MD, Florian Krammer, PhD, David Reich, MD, Carlos
Cordon-Cardo, MD, PhD
Author affiliations: Icahn School of Medicine at Mount Sinai, New York NY

12 Abstract

13 Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a

14 global pandemic. The percentage of infected individuals who seroconvert is still an open

15 question. In addition, it has been shown in some individuals that viral genome can still be

16 detected at considerable time post symptom resolution. Here we investigated both

17 seroconversion and PCR-positivity in a large cohort of convalescent serum donors in New York

18 City.

19 *Methods:* Individuals with confirmed or suspected SARS-CoV-2 infection were screened via

20 PCR for presence of viral genome and via enzyme-linked immunosorbent assay for presence of

- 21 anti SARS-CoV-2 spike antibodies.
- 22 *Results:* All but three confirmed SARS-CoV-2 patients seroconverted to the SARS-CoV-2 spike
- 23 while only 37.4% of suspected SARS-CoV-2 patients seroconverted. PCR-positivity was
- 24 detected up to 28 days from symptom resolution.

25	Conclusions: Here we show that the vast majority of confirmed COVID19 patients seroconvert,
26	potentially providing immunity to reinfection. We also report that in a large proportion of
27	individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks post
28	symptom resolution, but it is unclear if this signal represents infectious virus.
29	
30	
31	

32 Introduction

33 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around the 34 world, leading to unprecedented strain on health care systems and economies, causing over 35 290,000 infections and 17,000 deaths in New York State (source, New York State, Department of Health as of April 28th 2020) at the time of writing this report. Significant disruptions to daily 36 37 life have been enacted in order to flatten the epidemic curve. In order to avoid spread of SARS-38 CoV-2 and to help standardize definitions of clearance, it is important to understand the duration of SARS-CoV-2 nucleic acids within the nasopharynx and the time course to the mounting of an 39 40 antibody response to this new viral pathogen.

41 Current US Centers for Disease Control and Prevention (CDC) guidelines suggest that people

42 with confirmed or suspected SARS-CoV-2 infection should remain in isolation for at least seven

43 days from symptom onset and return to work if they have been asymptomatic for 72 hours.

44 However, to date, there are limited data that help to define the time to viral clearance from illness

45 onset and cessation of symptoms. A prior case study suggested that SARS-CoV-2 can exhibit

46	ongoing viral shedding for a median of 2.5 days (range 1-8 days) after complete symptom
47	resolution, but it remains unclear whether this viral shedding poses a risk for forward
48	transmission. ¹ A small case sample of four recently hospitalized patients found that they were
49	SARS-CoV-2 positive on repeat polymerase chain reaction (PCR) testing five to 13 days after
50	discharge. ² Other studies have found viral shedding for up to six weeks after symptoms. ³ From
51	work with the 2003 SARS-CoV-1it is not clear if detection of viral genome of this duration
52	indicates prolonged infectivity or presence of nonviable virus. ⁴ A clearer understanding of
53	duration of viral shedding is critical to preventing transmission by infected individuals,
54	particularly as they begin to feel well enough to resume normal activities. Understanding time to
55	PCR clearance may also help guide isolation durations and return to work clearance, as well as
56	clarify the utility of negative PCR testing as part of defining disease clearance.
57	There is limited data worldwide on the development of antibodies to SARS-CoV-2, particularly
57 58	There is limited data worldwide on the development of antibodies to SARS-CoV-2, particularly the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis
58	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis
	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis of SARS-CoV-2, little is known about long lasting immunity. One study measured neutralizing
58 59	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis of SARS-CoV-2, little is known about long lasting immunity. One study measured neutralizing antibodies in 175 hospitalized patients and found that 64% had high antibody titers, 30% had
58 59 60	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis of SARS-CoV-2, little is known about long lasting immunity. One study measured neutralizing
58 59 60 61	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis of SARS-CoV-2, little is known about long lasting immunity. One study measured neutralizing antibodies in 175 hospitalized patients and found that 64% had high antibody titers, 30% had weak antibody response, and 6% had undetectable titers. ⁵ Studying the plasma from previously
58 59 60 61 62	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis of SARS-CoV-2, little is known about long lasting immunity. One study measured neutralizing antibodies in 175 hospitalized patients and found that 64% had high antibody titers, 30% had weak antibody response, and 6% had undetectable titers. ⁵ Studying the plasma from previously infected individuals may further our understanding of the timing and strength of different
58 59 60 61 62 63	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis of SARS-CoV-2, little is known about long lasting immunity. One study measured neutralizing antibodies in 175 hospitalized patients and found that 64% had high antibody titers, 30% had weak antibody response, and 6% had undetectable titers. ⁵ Studying the plasma from previously infected individuals may further our understanding of the timing and strength of different populations' antibody response to this novel illness, delineate duration of antibody presence, and
58 59 60 61 62 63 64	the formation of IgG. While there is concern regarding efficacy of antibody testing for diagnosis of SARS-CoV-2, little is known about long lasting immunity. One study measured neutralizing antibodies in 175 hospitalized patients and found that 64% had high antibody titers, 30% had weak antibody response, and 6% had undetectable titers. ⁵ Studying the plasma from previously infected individuals may further our understanding of the timing and strength of different populations' antibody response to this novel illness, delineate duration of antibody presence, and identify cases of possible reinfection. Additionally, individuals with high antibody titers may

Here we present a large data set of serum antibody testing in persons who have fully recovered
after mild illness from SARS-CoV-2 at Mount Sinai Hospital. Our aim is to describe the time to

SARS-CoV-2 PCR clearance from the nasopharynx, the rates of IgG development, and time to
serum IgG development from onset and resolution of symptoms in 1,343 participants with prior
confirmed or suspected SARS-CoV-2 infection.

72

73 Methods

74 We conducted an outreach program in the New York City area, including parts of New York 75 State, Connecticut, and New Jersey, to identify people recovered from SARS-CoV-2 for nasopharyngeal PCR (cobas[®] SARS-CoV-2, Roche Diagnostics, Indiana) and serum IgG titer 76 measurement (ELISA Mount Sinai).^{9,10} Participants were tested between March 26 and April 10, 77 2020. We recruited participants via REDCap[®] (Vanderbilt University, Tennessee) online survey 78 79 response which was advertised on our hospital website, and subsequently shared by multiple 80 news organizations and public officials in New York. REDCap respondents were deemed 81 eligible if they had previously tested positive for SARS-CoV-2, or if they were symptomatic 82 with suspected SARS-CoV-2 and lived with someone with a positive SARS-CoV-2 PCR test, 83 had been told by a physician that they had symptoms consistent with SARS-CoV-2, or were 84 healthcare workers. We only included participants who self-reported suspicious symptoms after 85 February 1st 2020, as this is when it is believed SARS-CoV-2 began to spread in New York 86 City. Additionally, only participants who were asymptomatic at time of survey were 87 outreached. Respondents self-reported date of symptom onset, date of positive SARS-CoV-2 88 test (if applicable), and last date of symptoms. Duration of symptoms was calculated from these 89 self-reported dates.

90 During the first two weeks of the survey, we tested for SARS-CoV-2 in the nasopharynx by PCR 91 as well as IgG antibody (Ab) in the serum of every individual while in the third week the testing 92 was limited to SARS-CoV-2 antibodies only. The rationale for this change was that we had a far 93 larger testing volume combined with the fact that many of the participants reported symptom 94 resolution >14 days prior to testing. During week one, participants were brought in ten days after 95 they had a confirmed/suspected diagnosis and had been asymptomatic for at least three days. In 96 week 2, as we identified more potential donors and learned more about our antibody assay, we 97 extended our timeline to 14 days after symptoms onset, with at least three days asymptomatic. In 98 week 3, we included participants 21 days or more after symptom onset, who had been 99 completely asymptomatic for at least 14 days. 100 SARS-CoV-2 PCR was considered positive if detected on nasopharyngeal swab. We measured 101 serum IgG antibody titers using a serologic enzyme-linked immunosorbent assay (ELISA) 102 developed at Icahn School of Medicine at Mount Sinai and described on March 18, 2020; this 103 serum test has a sensitivity of 92% and a specificity >99%. Serum IgG titers were considered 104 "strongly positive" if they were detected at titers of 1:320 or higher (highest dilutions were 105 1:320, 1:960, 1:2880), and considered "weakly positive" if detected at titers of 1:80 and 1:160. 106 Negative was defined as titers below 1:80 (and is shown in figures as 1:40). All interested 107 participants with antibody titers >1:320 and negative SARS-CoV-2 PCR swabs were screened by 108 the New York Blood Center using standard criteria for plasma donation and included as donors 109 in our convalescent plasma study if eligible as per CFR Title 21. Participants with weakly 110 positive antibody titers were invited to return for repeat serum titer testing at least seven days 111 after their initial antibody test. Participants with positive PCR swabs and antibodies were asked 112 to return for PCR testing at least three days after initial PCR test so they could be referred for

- 113 plasma donation once the virus had fully cleared. Given the frequent serial detection of SARS-
- 114 CoV-2 by nasopharyngeal PCR using three-day increments, on April 3rd, 2020, we began to ask
- 115 participants to return at least ten days after the last positive PCR for re-testing.
- 116 One-way ANOVA and Fisher's exact test were used to measure the association of age, gender,
- symptom duration, and days from symptom onset and resolution with positive antibody results.
- 118 This study was reviewed and approved by our institutional review board.

119 **Results**

120 We measured SARS-CoV-2 antibody titers in 1,343 people over the first three weeks of the

survey (March 26, 2020 to April 10, 2020) using a now FDA approved two step ELISA.^{9,10} The

average age of the participants was 40 years (range 17 to 76 years) with 256 (19%) between the

123 ages of 17 and 29, 968 (72%) age 30-59, and 119 (9%) 60 or older. Fifty three percent were

male and 47% had confirmed SARS-CoV-2 diagnosis by prior PCR testing. Median days

between symptom onset to serum antibody test was 24 days (range 3 -70), median days between

symptom resolution to antibody test was 15 (4-77) and median duration of symptoms was 9 days

127 (1-67). Of the 1,343 total participants, almost all were outpatients who had experienced mild to

128 moderate symptoms, and only 3% were seen in our emergency department or hospital.

Seven hundred and sixty-one (57%) participants of the total sample were antibody positive, 61
(5%) were weakly positive, and 521 (39%) were negative. Neither age, gender, nor symptom
duration was associated with antibody response. In the 584 participants for whom both
nasopharyngeal PCR testing and serum antibody testing was available, SARS-CoV-2 RNA was
detected in 249 (42%) at a median of 20 days from symptom onset (range 11-43) and 12 days
from symptom resolution (range 5-28).

135 Six hundred and twenty-four participants had confirmed SARS-CoV-2 disease by PCR prior to 136 coming for testing, either by self-report or documented in our electronic medical record; if self-137 reported, participants provided the date of testing. In this subgroup the average age was 39 138 (range 17-76) and 59% were male. At first test, five hundred and eleven (82%) were strongly 139 antibody positive at titer >= 1:320, 42 (7%) were weakly positive, and 71 (11%) were negative 140 (Figure 1A). We asked the 18% with initial negative or weakly positive antibody response to 141 return for a second test ten or more days later. At the time of the first test, 217 (35%) were still 142 PCR positive (range 5-22 days from symptom resolution) (Figure 2). Median duration of 143 symptoms in this group was nine days (range 1-31). Neither age nor sex was associated with a 144 strong antibody response. Greater number of days between symptom onset and antibody test 145 was associated with a higher titer antibody test (23 days versus 20 days). Symptom duration was 146 also associated with higher antibody titers (9 days versus 7 days). (**Table 2**)

In the subgroup of 719 participants with suspected disease that did not have confirmed SARS-CoV-2 infection, average age was 41 (17-76) and 47% were male. 250 (35%) were strongly antibody positive, 19 (3%) were weakly positive, and 436 (62%) were negative. Antibodies were measured a median of 28 days from symptom-onset and 19 days from date of symptom resolution. In this group, neither age, gender, nor symptom duration was associated with stronger antibody response. (**Table 1**)

Of the 113 participants with PCR confirmed SARS-CoV-2 and weakly positive or negative titers on their first serum antibody test, 64 have returned for follow up antibody titers at the time of submission. Of these, 57 (89%) displayed increased titers between the two tests, a median of 13 days (5-25) later (**Figure 1B**). Four remained weakly positive, and three remained negative.

157 The three that remained negative all self-reported positive PCR testing (none were documented158 in our EMR). (Table 2)

While all survey participants self-reported complete resolution of symptoms three to 14 or more days prior to testing, 249 (19%) tested positive for nasopharyngeal SARS-CoV-2 RNA. The maximum time of positive nasopharyngeal PCR testing was 43 days from symptom onset and 28 days from symptom resolution. For the 182 individuals who returned for repeat nasopharyngeal swabbing at least three days after prior positive test, 61% were negative on the repeat test, a median of 10 days (range 3-21) after the first test. Seventy (39%) remained positive and were

rescheduled for another nasopharyngeal PCR 7-10 days later. (**Table 3**).

166 Discussion

Our survey provides a large cross-sectional representation of SARS-CoV2 RNA and antibodies found in participants recruited after recovery from SARS-CoV-2 during the early weeks of the outbreak in New York City. Understanding the duration of potential infectiousness and the time to IgG antibody response are critical to the containment of SARS-CoV-2 spread, and the plans for widespread antibody testing over the coming months. Some countries, states and organizations may even be considering antibody testing prior to letting individuals return to work.

In contrast to some of the prior literature on formation of antibodies, over 99% of the patients
who self-reported or had laboratory documented SARS-CoV-2 infection developed IgG
antibodies using our assay. Additionally, our findings suggest that IgG antibodies develop over a
period of 7 to 50 days from symptom onset and 5 to 49 from symptom resolution, with a median
of 24 days from symptom onset to higher antibody titers, and a median of 15 days from symptom

resolution to higher antibody titers. This suggests that the optimal time frame for widespread
antibody testing is at least three to four weeks after symptom onset and at least two weeks after
symptom resolution. In our survey, we did not find evidence for a decrease in IgG antibody titer
levels on repeat sampling.

Although we do not yet know what, if any, immunity is conferred by IgG or the duration of the 183 184 IgG response, at this time it seems likely that IgG to SARS-CoV-2 may confer some level of 185 immunity based on what is known about viral immunity to other pathogens. In prior studies of SARS-CoV-1 and Middle East Respiratory Syndrome patients, IgG peaked within months of 186 primary infection and waned over time.¹¹⁻¹³ Similar observations have been made with human 187 coronaviruses were immunity can confer at least limited protection.¹³ In order to study the 188 189 duration of IgG antibody response to SARS-CoV-2, we plan to follow our cohort for the next six 190 months in order to track titer levels.

Among participants who did not have prior PCR but who were deemed high risk, i.e., people 191 192 with symptoms consistent with SARS-CoV-2 who were told by a healthcare provider they had 193 presumed infection, lived with someone with confirmed infection, or were healthcare workers 194 themselves, we found 36% of this population had IgG antibodies to SARS-CoV-2. This finding 195 suggests that a majority of participants suspected of having Covid-19 actually were not infected 196 with SARS-CoV-2; however, it may also include a false negative rate of our assay (which has a 197 92% sensitivity) or insufficient time for participants to mount an IgG antibody response. This 198 underscores the importance of expanded PCR testing in order to improve diagnosis of this 199 disease even in minimally symptomatic individuals.

200 The 19% of participants who remained PCR positive despite self-reporting full resolution of 201 symptoms bring to light important considerations regarding the possible duration of viral 202 transmission, and the limited utility of PCR testing to ensure clearance. This positive PCR 203 finding could represent shedding of nonviable virus, non-infectious genome fragments or viruses 204 engulfed by immune cells, asymptomatic carriers of SARS-CoV-2, or ongoing disease despite 205 full resolution of symptoms. Detection of viral genome even months after resolution of infection has been shown for viruses like measles virus.¹⁴ Further studies are warranted to determine if 206 207 nasopharyngeal PCR positivity is related to transmission, and if so, for how long. This will have 208 significant implications in terms of guidance of when recovered SARS-CoV-2 individuals should 209 end self-isolation, currently recommended at least seven days after symptom onset with at least 210 72 hours without fever off of antipyretics. If PCR positivity is a result of identifying 211 noninfectious genome or nonviable virus, it may be necessary to avoid use of PCR as a definition 212 of clearance in SARS-CoV-2.

213 There are limitations to our evaluation. All participants had mild disease, and thus these data 214 may not reflect PCR or Ab findings in a moderately or severely ill population. Participants were 215 recruited based on self-referral and self-reporting, which may have led to recall bias in terms of dates of symptom onset, resolution and duration, and may have led us to miss asymptomatic 216 217 carriers who did not inquire about testing. Additionally, given recruitment via an English-218 language online survey and our use of a single collection site, our sample likely included more 219 recovered participants of younger ages with internet access and the ability to travel to our site for 220 testing. Furthermore, we did not collect rigorous data regarding symptom severity which could 221 potentially be related to the timeline and strength of IgG antibody response to SARS-CoV-2.

222	Future studies are planned to help us understand the magnitude and duration of the IgG response
223	in patients recovered from SARS-CoV-2, and what antibody titer may be necessary to protected
224	individuals from reinfection. We also hope to better understand which, if any, patients do not
225	mount an IgG immune response. Finally, the clinical significance of prolonged positive SARS-
226	CoV-2 nasopharyngeal PCR in the absence of symptoms requires further clarification.
227	Conclusion

- 228 Duration of nasopharyngeal PCR SARS-CoV-2 PCR detection and time to mount IgG antibody
- response have important implications for the spread of this virus and risk for re-infection among
- individuals. In our sample, we found that 19% of people continue to have nasopharyngeal PCR
- 231 positivity two or more weeks after symptom resolution, and that it takes three or more weeks to
- mount an IgG antibody response believed to be potentially protective against future infection.
- 233 Reassuringly, we found that almost all participants with confirmed SARS-CoV-2 infection in our
- study mounted an IgG immune response to this disease. Taken together, these findings will be
- 235 pivotal in understanding disease activity of SARS-CoV-2 moving forward.
- 236
- 237

238 Acknowledgements

- Thank you to all the patients who generously came in for testing and plasma donation. Thanks toKim Stone and Kim Muellers for their work on data analysis.
- 241 Work on SARS-CoV-2 immunity in the Krammer is supported by the National Institute of
- 242 Allergy and Infectious Disease (NIAID) Collaborative Influenza Vaccine Innovation Centers
- 243 (CIVIC) contract 75N93019C00051 and the NIAID Centers of Excellence for Influenza
- Research and Surveillance (CEIRS) contract HHSN272201400008C as well as institutional and
- 245 philanthropic funding.

Table 1.

	Respondents with past PCR+ confirmed SARS-CoV-2				
				р-	
	(n=624)	Ab+ (511)	Ab Weak + (42)	Ab- (71)	value
	39.14	39.11		40.00	
Age, Mean (SD)	(12.09)	(11.94)	38.10 (12.28)	(13.19)	0.716
Age, Range	17 - 76	17 - 76	18 - 67	19 - 74	
Age by Category, N (%)					0.117
17-29	144 (23%)	110 (22%)	• •	19 (27%)	
30-59	432 (69%)	364 (71%)	· · ·	44 (62%)	
60+	48 (8%)	37 (7%)	3 (7%)	8 (11%)	
Gender					0.002
Male, N (valid %)	368 (59%)	303 (60%)	33 (81%)	32 (46%)	
Female, N (valid %)	252 (41%)	206 (40%)	8 (19%)	38 (54%)	
Test Results, N (%)					
All Still PCR+ at next test	217 (35%)	159 (31%)	22 (52%)	36 (51%)	
PCR+/Ab+	159 (26%)	-	-	-	-
PCR-/Ab-	18 (3%)	-	-	-	-
PCR-/Ab+	95 (15%)	-	-	-	-
PCR+/Ab-	36 (6%)	-	-	-	-
PCR-/Abweak+	7 (1%)	-	-	-	-
PCR+/Abweak+	22 (4%)	-	-	-	-
No new PCR/Ab+	257 (41%)	-	-	-	-
No new PCR/Abweak+	13 (2%)	-	-	-	-
No new PCR/Ab-	17 (3%)	-	-	-	_
Time from last PCR+ to					
Current Result, Median days					
(Range)	19 (8-54)	19 (8-49)	18 (8-26)	17 (10-54)	0.004
Symptoms, Median days	, ,	()	()	()	
(Range)					
(<0.00
Onset to Result	23 (3-46)	23 (1-46)	20 (15-28)	21 (14-34)	1
Resolution to Result	14 (4-49)	14 (-1-49)		12 (4-25)	0.013
Symptom Duration	9 (1-31)		. ,	10 (2-27)	0.017
			D past PCR+, susp		
	All				p-
	(n=719)	Ab+ (250)	Ab Weak + (19)	Ab- (450)	value
	41.39	39.49		42.44	
Age, Mean (SD)	(12.16)	(12.76)	41.53 (12.73)	(11.69)	0.009
Age, Range	17 - 76	17 - 76	27 - 71	21 - 75	
Age by Category, N (%)					0.008
17-29	112 (16%)	55 (22%)	4 (21%)	53 (12%)	
30-59	536 (75%)	174 (70%)	12 (63%)	350 (78%)	
60+	71 (10%)	21 (8%)	3 (16%)	47 (10%)	
Gender	/ 1 (10/0)	21(0/0)	5 (10/0)	-, (TO/0)	0.388
Male, N (valid %)	338 (47%)	123 (49%)	11 (58%)	204 (45%)	0.500
iviaic, iv (valia 70)	550 (4770)	123 (43/0)	TT (2070)	204 (4370)	

Female, N (valid %)	381 (53%)	127 (51%)	8 (42%)	246 (55%)	
Live with someone tested			. (= . ()		
pos?	62 (9%)	33 (13%)	1 (5%)	28 (6%)	0.061
Had direct patient contact?	69 (10%)	24 (10%)	1 (5%)	44 (10%)	0.293
Told by doctor had COVID-					
19?	264 (23%)	115 (46%)	10 (53%)	139 (31%)	0.020
Test Results, N (%)					
PCR+/Ab+	24 (3%)	-	-	-	
PCR-/Ab-	174 (24%)	-	-	-	
PCR-/Ab+	38 (5%)	-	-	-	
PCR+/Ab-	7 (1%)	-	-	-	
PCR-/Abweak+	3 (1%)	-	-	-	
PCR+/Abweak+	1 (0%)	-	-	-	
No PCR/Ab+	188 (26%)	-	-	-	
No PCR/Abweak+	15 (2%)	-	-	-	
No PCR/Ab-	269 (37%)	-	-	-	
Symptoms, Median days					
(Range)					
					<0.00
Onset to Result	28 (3-70)	26 (7-50)	26 (22-30)	32.5 (3-70)	1
		. ,		. ,	<0.00
Resolution to Result	19 (5-70)	18 (5-34)	17 (10-57)	21.5 (5-70)	1
Symptom Duration	9 (2-67)	8 (2-67)	10 (5-21)	10 (2-43)	0.021

246

247


248 Table 2.

		Antibody Pts with 2nd Ab test as of 4/24 (N=64)			
			Test		
	Test 1	Test 2	3		
	*1st test restricted to 4/10	*2nd test 4/22 or			
Antibody result, N (%)	or earlier	earlier			
positive	-	48 (75%)	2 (3%)		
weakly positive	19 (30%)	13 (20%)	-		
negative	45 (70%)	3 (5%)	-		
Time Bw results 1 & 2, Median (Range)	13 (5-25)		-		
Change in result, N (%)					
neg to pos	33 (52%)	-	-		
neg to weak pos	9 (14%)	-	-		
neg to neg	3 (5%)	-	-		
weak pos to pos	15 (23%)	-	-		
weak pos to neg	0 (0%)	-	-		
weak pos to weak pos	4 (6%)	-	-		

Time bw results by result change, Median			
(Range)			
neg to pos	14 (5-22)	-	-
neg to weak pos	12 (6-19)	-	-
neg to neg	14 (12-15)	-	-
weak pos to pos	11 (7-16)	-	-
weak pos to neg	-	-	-
weak pos to weak pos	14.5 (13-18)	-	-
Symptoms, Median days (Range)			
		31.5 (20-	
Onset to Result	19 (2-31)	42)	-
Resolution to Result	12 (4-25)	24 (12-32)	_
Symptom Duration	5 (2-27)	-	-


- **Table 3.**

		PCR			
	Pts with 2nd PCR test as of 4/24 (N=182)				
	Test 1 Test 2		Test 3		
	*1st test restricted to	*2nd test 4/22 or			
PCR result, N (%)	4/10 or earlier	earlier			
Detected	182 (100%)	70 (39%)	8 (57%)		
Not Detected	-	112 (61%)	6 (43%)		
Time Bw results 1 and 2, Median (Range)	10 (3-21)	-	-		
Change in result, N (%)					
Detected to Detected	70 (39%)	-	-		
Detected to Not Detected	12 (61%)	-	-		
Time bw results by result change, Median					
(Range)					
Detected to Detected	10 (3-21)	-	-		
Detected to Not Detected	10 (4-21)	-	-		
Symptoms, Median days (Range)					
Onset to Result	20 (1-43)	30 (6-50)	-		
Resolution to Result	12 (-1-20)	22 (4-34)	-		
Symptom Duration	8 (1-27)	-	-		



268

Figure 1: Antibody responses in PCR-confirmed COVID19 individuals. A shows antibody testing results days post symptom onset stratified into titer categories. The highest titer category contains both 1:2880 and >1:2880 titers. Bars represent the mean; error bars the standard deviation. B Individuals with negative titers were recalled for retesting. Both the original test result and the second test result post day onset are shown. Negative titers were assigned a value of 1:40 for representation purpose, the line represents the cut-off between positive and negative titers. Only results for individuals for which date of symptom onset is known are shown.



days post symptom resolution

Figure 2: PCR results of initially PCR-confirmed COVID19 individuals. Viral genome was
detected in nasopharyngeal swaps of individuals screened as plasma donors. Number of subjects
positive or negative days post symptom resolution are shown. More than one result from an
individual might be shown if tested more than once on different days. Only results for subject for
which a date of symptom resolution was available are shown.

- 282 283 284
- 285
- 286
- 287
- 288
- 289
- 290

291 **References**

- 292
- 2931.Chang, Mo G, Yuan X, et al. Time Kinetics of Viral Clearance and Resolution of Symptoms294in Novel Coronavirus Infection. Am J Respir Crit Care Med 2020.
- 295 2. Lan L, Xu D, Ye G, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-296 19. JAMA 2020.
- 297 3. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56
 298 COVID-19 patients. Clin Infect Dis 2020.
- 299 4. Chu CM, Leung WS, Cheng VC, et al. Duration of RT-PCR positivity in severe acute
 300 respiratory syndrome. Eur Respir J 2005;25:12-4.
- 301 5. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-
- 302 19 recovered patient cohort and their implications. medRxiv 2020:2020.03.30.20047365.
- 303 6. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-304 19 patients. Proc Natl Acad Sci U S A 2020.

- 3057.Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the306prevention and treatment of COVID-19. J Clin Invest 2020.
- 307 8. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically III Patients With COVID-19 With
 308 Convalescent Plasma. JAMA 2020.
- 309 9. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2
 310 seroconversion in humans. medRxiv 2020:2020.03.17.20037713.
- 311 10. Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 Seroconversion in Humans: A
- Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc
 Microbiol 2020;57:e100.
- 11. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARSassociated coronavirus after recovery. N Engl J Med 2007;357:1162-3.
- 316 12. Al-Abdely HM, Midgley CM, Alkhamis AM, et al. Middle East Respiratory Syndrome
- Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients,
- 318 Saudi Arabia. Emerg Infect Dis 2019;25:753-66.
- 319 13. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody
- 320 mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and
- 321 association of antibody responses with severity of disease. medRxiv
- 322 2020:2020.04.14.20065771.
- 14. Lin WH, Kouyos RD, Adams RJ, Grenfell BT, Griffin DE. Prolonged persistence of measles
- 324 virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A
- 325 2012;109:14989-94.
- 326